The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a modified benzoxazine moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.

 
Web www.patentalert.com

< Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

> Haloalkyl ester derivatives of coumarin for the treatment of coagulation disorders

> Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands

~ 00595